# vergegenomics.com > AI-optimized mirror of vergegenomics.com containing 27 pages totalling 17,388 words of clean markdown content, structured data, and semantic HTML. Original source: https://vergegenomics.com. Last updated: 2026-07-18T01:53:37.051Z. Each page is available as HTML (with JSON-LD structured data) and Markdown (text-only, ideal for LLMs and RAG). ## Homepage - [Verge Labs | Frontier AI for human biology](/content/site-root.html): Verge Labs has spent a decade building one of the most comprehensive proprietary human tissue datasets in neurological disease. (449 words) ## Articles & Blog Posts - [vergelabs-com/resources/reports/index.html](/content/vergelabs-com/resources/reports/index.html) (487 words) - [Introducing vBx-1.0 | Reports | Verge Labs](/content/vergelabs-com/resources/reports/vbx-one-technical-report/index.html): Verge’s multi-modal foundation model for precision neurology (4,301 words) - [Privacy Policy | Verge Labs](/content/vergelabs-com/privacy-policy/index.html): How Verge Genomics collects, uses, and protects your personal information. (3,604 words) - [Resources | Verge Labs](/content/vergelabs-com/resources/index.html): News, publications, and writing from the team at Verge Labs. (535 words) - [Positive Phase 1 safety and tolerability data for VRG50635 | News | Verge Labs](/content/vergelabs-com/resources/news/vrg50635-phase1-safety/index.html): Verge Genomics completed the Phase 1 trial of VRG50635 in 80 healthy adult volunteers with no serious adverse events, supporting advancement into a proof-of-concept study in people with ALS later this year. (632 words) - [Publications | Verge Labs](/content/vergelabs-com/resources/publications/index.html): Peer-reviewed papers, preprints, and manuscripts in submission from the Verge Labs research team. (388 words) - [First-in-human dosing of VRG50635 begins in Phase 1 trial | News | Verge Labs](/content/vergelabs-com/resources/news/vrg50635-first-in-human/index.html): The first subject has been dosed in the Phase 1 trial of VRG50635, a PIKfyve inhibitor for ALS discovered using the CONVERGE platform. The randomized, placebo-controlled study evaluates safety, tolerability, and pharmacokinetics in healthy volunteers and people with ALS. (385 words) - [Partnerships | Verge Labs](/content/vergelabs-com/partnerships/index.html): Verge Labs partners with leading pharmaceutical and biotech companies — over $1.6B in announced deal value — to discover new targets and de-risk neuroscience drug development. (260 words) - [Mission | Company | Verge Labs](/content/vergelabs-com/company/index.html): Verge Labs is a frontier AI lab building world models of human disease biology, starting from a decade of multi-modal patient data. (310 words) - [New approach for uncovering novel drug targets from human genetics published in PLOS Computational Biology | News | Verge Labs](/content/vergelabs-com/resources/news/bagea-publication/index.html): Verge Genomics published BAGEA, a statistical framework for inferring the functional impact of genetic variants directly from sequence data. The method addresses a key bottleneck in translating human genetic data into actionable therapeutic targets. (442 words) - [Fierce Biotech names Verge Genomics a 2022 “Fierce 15” biotech company | News | Verge Labs](/content/vergelabs-com/resources/news/fierce-15-2022/index.html): Verge Genomics was named to Fierce Biotech’s 2022 “Fierce 15” list, recognizing the biopharma industry’s most promising early-stage companies. The honor follows a $98M oversubscribed financing and the three-year, $706M ALS partnership with Eli Lilly. (396 words) - [Verge Genomics and Eli Lilly announce three-year ALS collaboration | News | Verge Labs](/content/vergelabs-com/resources/news/lilly-collaboration-2021/index.html): A three-year collaboration with Eli Lilly will apply Verge Genomics’ AI-driven all-in-human platform to discover and develop novel ALS therapies. Verge receives up to $25M upfront and equity, with $694M in potential milestone payments plus downstream royalties. (401 words) - [Verge Genomics and the Pritzker Consortium form schizophrenia research collaboration | News | Verge Labs](/content/vergelabs-com/resources/news/pritzker-schizophrenia/index.html): A new collaboration with the Pritzker Neuropsychiatric Disorders Research Consortium will apply the CONVERGE® platform to postmortem brain tissue data from schizophrenia patients, with the aim of identifying novel therapeutic targets for a refractory disease area. (385 words) - [Alice Zhang honored by Goldman Sachs as one of 2022’s Most Exceptional Entrepreneurs | News | Verge Labs](/content/vergelabs-com/resources/news/goldman-sachs-honor/index.html): Goldman Sachs recognized Verge Genomics CEO and co-founder Alice Zhang as one of the Most Exceptional Entrepreneurs of 2022 at its Builders and Innovators Summit in Healdsburg, California. (299 words) - [Verge Genomics and Alexion launch AI-enabled drug discovery collaboration for rare neuro diseases | News | Verge Labs](/content/vergelabs-com/resources/news/alexion-collaboration/index.html): A four-year, multi-target collaboration with Alexion, AstraZeneca Rare Disease will apply the CONVERGE™ platform to identify therapies for rare neurodegenerative and neuromuscular diseases. Total deal value up to $840M plus royalties; AstraZeneca takes an equity position. (309 words) - [Verge Labs Unveils vBx: A Breakthrough Foundation Model for Precision Neurology | News | Verge Labs](/content/vergelabs-com/resources/news/vbx-launch/index.html): The new ‘virtual biopsy’ model predicts brain activity, therapy response, and side effects in patients with up to 3x greater accuracy than previous state-of-the-art models. (528 words) - [Alice Zhang named to Fortune 40 Under 40 and Fierce Biotech’s Fiercest Women in Life Sciences | News | Verge Labs](/content/vergelabs-com/resources/news/alice-zhang-fortune-fierce/index.html): Verge Genomics CEO and co-founder Alice Zhang was recognized by Fortune in the health/bioscience category of its 2022 40 Under 40, and by Fierce Biotech as one of the year’s Fiercest Women in Life Sciences. (292 words) - [Lilly selects two ALS targets from CONVERGE® collaboration | News | Verge Labs](/content/vergelabs-com/resources/news/lilly-milestones-2024/index.html): Eli Lilly has elected to pursue therapeutics against two validated ALS targets identified by Verge Genomics’ AI-enabled CONVERGE® platform — triggering near-term milestone payments and continuing the three-year partnership announced in 2021. (408 words) - [Verge Labs and Tenacia Biotechnology Partner to Advance Tenacia’s CNS Pipeline Using Human Data | News | Verge Labs](/content/vergelabs-com/resources/news/tenacia-cns-partnership/index.html): First partnership announced under Verge Labs’ platform-first model; Tenacia will apply Verge’s AI platform and proprietary multimodal human tissue data to characterize targets across select CNS programs. (525 words) - [Applications | Platform | Verge Labs](/content/vergelabs-com/platform/applications/index.html): CONVERGE: the AI operating system for neuroscience drug development. Novel target discovery, program enablement, and clinical trial optimization, powered by Verge's foundation model of patient biology. (498 words) - [Digital biomarkers detect short-term ALS progression in VRG50635 trial run-in | News | Verge Labs](/content/vergelabs-com/resources/news/digital-biomarkers-vrg50635/index.html): In the pre-treatment run-in for the VRG50635 ALS proof-of-concept study, multiple at-home digital endpoints — mobility, breathing, sleep, and speech — captured statistically significant changes in just eight weeks, pointing to a more sensitive design for ALS clinical trials. (279 words) - [VRG50635 proof-of-concept study initiated in patients with ALS | News | Verge Labs](/content/vergelabs-com/resources/news/vrg50635-poc-initiation/index.html): Verge Genomics initiated a Phase 1b proof-of-concept study of VRG50635, a PIKfyve inhibitor for sporadic and familial ALS. The trial uses at-home digital devices to collect dense, objective measurements of disease progression and treatment response. (323 words) - [Data | Platform | Verge Labs](/content/vergelabs-com/platform/index.html): VergeDB: a decade of multi-modal patient brain data assembled from 12,000 brains through 21+ institutional partnerships. (351 words) - [Models | Platform | Verge Labs](/content/vergelabs-com/platform/models/index.html): A world model of patient biology: Verge's first multi-modal biological foundation model designed to reason about neurological disease at the patient level. (240 words) - [Blog | Verge Labs](/content/vergelabs-com/resources/blog/index.html): Long-form writing from the Verge Labs team — published on Substack. (32 words) - [News | Verge Labs](/content/vergelabs-com/resources/news/index.html): Announcements, partnerships, and milestones from Verge Labs. (329 words) ## Resources - [Full Page Index](/index.html): Browse all cached pages with rich metadata - [About This Cache](/content/about.html): Methodology, technical details, and usage guidelines - [XML Sitemap](/sitemap.xml): Machine-readable sitemap for crawler discovery - [Robots.txt](/robots.txt): Crawler directives